The Institute of Cancer Research
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
'What a legacy': Pioneering researcher Richard Scolyer dies aged 59
Professor Richard Scolyer dies aged 59 leaving behind legacy of revolutionary brain cancer research Mon 8 Jun 2026 at 12:06am Former Australian of the Year Professor Richard Scolyer has died aged 59 after fighting the "worst of the worst brain cancers". His legacy: fast-tracking revolutionary cancer treatment by volunteering to be "patient zero" in a radical approach to treating his tumour. Scolyer fought the aggressive brain cancer for almost three years, defying the terrible survival odds.
Cancer’s favorite escape trick may actually make it easier to kill
Cancer’s favorite escape trick may actually make it easier to kill - Date: - June 4, 2026 - Source: - Baylor College of Medicine - Summary: - Scientists have uncovered a surprising new way the immune system fights cancer, overturning a core belief that has guided immunology for decades. The research found that when cancer cells shut down a key immune-recognition molecule called MHC I—a common trick used to hide from “killer” T cells—they can actually become more vulnerable to attack by a...
Scientists found the hidden switch fueling alzheimer’s brain inflammation
Scientists found the hidden switch fueling alzheimer’s brain inflammation Scientists may have found a hidden Alzheimer’s “inflammation switch”—and turning it off protected brain connections in early studies. - Date: - May 31, 2026 - Source: - Scripps Research Institute - Summary: - Scientists at Scripps Research have uncovered a molecular “switch” that appears to fuel the damaging brain inflammation seen in Alzheimer’s disease. They found that a protein called STING becomes chemically...
One fat helped pancreatic cancer grow while another cut disease in half
One fat helped pancreatic cancer grow while another cut disease in half - Date: - June 2, 2026 - Source: - Yale School of Medicine - Summary: - A surprising new study suggests that when it comes to pancreatic cancer, the kind of fat you eat may matter more than how much. Researchers found that oleic acid—the main fat in olive oil and several other common foods—sped up tumor growth in mice predisposed to pancreatic cancer, while omega-3-rich fats from fish oil dramatically slowed disease...
A prognostic human brain network for diffuse midline glioma
Abstract Diffuse midline gliomas (DMGs) are near-universally lethal tumours of the childhood central nervous system1,2. In animal models, DMGs form brain-wide integrated networks through neuron-to-glioma synapses3,4,5,6 and glioma-to-glioma gap junctional coupling3. This extensive connectivity robustly promotes the growth and invasion of DMG3,4,5,6,7,8,9 and other glial malignancies10,11,12 through paracrine mechanisms and direct neuron-to-glioma synapses.
Why are sloths slow? It's in their DNA
It's in their DNA Lisa Lock Scientific Editor Robert Egan Associate Editor Sloths are the slowest mammals on the planet, but living in dense jungles has made them notoriously difficult to study. For the first time, scientists have now sequenced and analyzed the two-toed sloth genome and revealed the genetics behind its extremely slow metabolism. Building on work initiated at the Leibniz Institute for Zoo and Wildlife Research (IZW) in Berlin, Germany, researchers at the Wellcome Sanger...
Fear of recurrence: How immune memory helps cancer survivors face their worst nightmare
Every year the world observes National Cancer Survivors Month in June, celebrating the growing number of people who have successfully completed cancer treatment and are building lives beyond their diagnosis. For many survivors, however, the end of treatment does not always bring complete peace of mind. Even years later, routine scans, follow-up appointments or unexplained aches can revive a lingering question: What if the cancer comes back?
Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery
Durvalumab shows promising results in trial led by London-based Institute of Cancer ResearchDoctors are hailing a drug that spares bladder cancer patients “life-changing” surgery and stops tumours coming back. Bladder cancer is the ninth most common cancer in the world. Advanced or aggressive forms are often treated with surgery to remove the entire bladder, with patients left having to find alternative ways to pass urine for the rest of their life.
Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery
Durvalumab shows promising results in trial led by London-based Institute of Cancer ResearchDoctors are hailing a drug that spares bladder cancer patients “life-changing” surgery and stops tumours coming back. Bladder cancer is the ninth most common cancer in the world. Advanced or aggressive forms are often treated with surgery to remove the entire bladder, with patients left having to find alternative ways to pass urine for the rest of their life.
Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery
Durvalumab shows promising results in trial led by London-based Institute of Cancer ResearchDoctors are hailing a drug that spares bladder cancer patients “life-changing” surgery and stops tumours coming back. Bladder cancer is the ninth most common cancer in the world. Advanced or aggressive forms are often treated with surgery to remove the entire bladder, with patients left having to find alternative ways to pass urine for the rest of their life.